Friday, July 10, 2026

pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy

Biogen

Biogen is a pharma organization headquartered in VISAKHAPATNAM, IN. Primary therapeutic focus areas include Relapsing-Remitting Multiple Sclerosis, Spinal Muscular Atrophy, systemic lupus erythematosus, IgA nephropathy,

225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Clinical program

Spinraza 12 mg solution for injection

Approved · small molecule · Spinal Muscular Atrophy

Spinraza 12 mg solution for injection for Spinal Muscular Atrophy is a Approved program (small_molecule) at Biogen with 1 ClinicalTrials.gov record(s).

← All Biogen projects Approved small molecule active

Internal code 232SM404

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Biogen
Phase
Approved
Modality
small_molecule
Indication
Spinal Muscular Atrophy
Status
active
Trials
1